Evidence map›Paper›PMID 42380605›Full record

Reviewnpj drug discovery2026

Quantum-machine-assisted drug discovery.

Yidong Zhou, Jintai Chen, Jinglei Cheng, Xu Cao, Yuanyuan Zhang, Gopal Karemore, Marinka Zitnik, Frederic T Chong, Junyu Liu, Tianfan Fu and 1 more

Abstract readReview
In one paragraph

Review in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yidong Zhou *Rensselaer Polytechnic Institute, Troy, NY, USA.
Jintai Chen *University of ILlinois at Urbana-Champaign, Champaign, IL, USA.
Jinglei ChengUniversity of Pittsburgh, Pittsburgh, PA, USA.
Xu CaoUniversity of ILlinois at Urbana-Champaign, Champaign, IL, USA.
Yuanyuan ZhangPurdue University, West Lafayette, USA.
Gopal KaremoreNovo Nordisk A/S, Måløv, Denmark.
Marinka ZitnikHarvard University, Cambridge, MA, USA.
Frederic T ChongUniversity of Chicago, Chicago, IL, USA.
Junyu LiuUniversity of Pittsburgh, Pittsburgh, PA, USA. junyuliucaltech@gmail.com.
Tianfan FuRensselaer Polytechnic Institute, Troy, NY, USA. futianfan@gmail.com.
Zhiding LiangRensselaer Polytechnic Institute, Troy, NY, USA. zlianghahaha@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug discovery is lengthy and expensive, with traditional computer-aided design facing limits. This paper examines integrating quantum computing across the drug development cycle to accelerate and enhance workflows and rigorous decision-making. It highlights quantum approaches for molecular simulation, drug-target interaction prediction, and optimizing clinical trials. Leveraging quantum capabilities could accelerate timelines and costs for bringing therapies to market, improving efficiency and ultimately benefiting public health.

Identifiers

PMID42380605
PMCPMC13252866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.